Folia Neuropathologica
eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

The role of synaptic plasticity in Alzheimer’s disease: from molecular mechanisms to therapeutic targets

Yunyun Li
1
,
Sichong Li
1
,
Jing Ma
1
,
Jing Zhao
2
,
Ning Ning
1
,
Jianfang Sun
2

  1. Department of Neurology, The 942nd Hospital of PLA Joint Logistics Support Force, Yinchuan, Ningxia Hui Autonomous Region 750001, China
  2. Cadre Ward, The 942nd Hospital of PLA Joint Logistics Support Force, Yinchuan, Ningxia Hui Autonomous Region 750001, China
Folia Neuropathol 2025; 63
DOI: https://doi.org/10.5114/fn.2025.156508
Online publish date: 2025/12/21
Article file
- The role of synaptic.pdf  [0.24 MB]
Get citation
 
PlumX metrics:
 
1. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement 2023; 19: 1598-1695.
2. Appelbaum LG, Shenasa MA, Stolz L, Daskalakis Z. Synaptic plasticity and mental health: methods, challenges and opportunities. Neuropsychopharmacology 2023; 48: 113-120.
3. Armato U, Chakravarthy B, Pacchiana R, Whitfield JF. Alzheimer’s disease: an update of the roles of receptors, astrocytes and primary cilia (review). Int J Mol Med 2013; 31: 3-10.
4. Barakos J, Purcell D, Suhy J, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 2022; 9: 211-220.
5. Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer’s disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimers Dement 2015; 11: 1349-1357.
6. Bedoya-Guzman FA, Pacheco-Herrero M, Salomon-Cruz ID, Barrera-Sandoval AM, Gutierrez Vargas JA, Villamil-Ortiz JG, Villegas Lanau CA, Arias-Londoño JD, Area-Gomez E, Cardona Gomez GP. BACE1 and SCD1 are associated with neurodegeneration. Front Aging Neurosci 2023; 15: 1194203.
7. Browne D, McGuinness B, Woodside JV, McKay GJ. Vitamin E and Alzheimer’s disease: what do we know so far? Clin Interv Aging 2019; 14: 1303-1317.
8. Chen ZY, Zhang Y. Animal models of Alzheimer’s disease: Applications, evaluation, and per-spectives. Zool Res 2022; 43: 1026-1040.
9. Chou YH, Sundman M, Ton That V, Green J, Trapani C. Cortical excitability and plasticity in Alzheimer’s disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies. Ageing Res Rev 2022; 79: 101660.
10. Fakhoury M. Inflammation in Alzheimer’s disease. Curr Alzheimer Res 2020; 17: 959-961.
11. Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Involvement of p38 MAPK in synaptic function and dysfunction. Int J Mol Sci 2020; 21: 5624.
12. Fan LZ, Kim DK, Jennings JH, Tian H, Wang PY, Ramakrishnan C, Randles S, Sun Y, Thadhani E, Seok Kim Y, Quirin S, Giocomo L, Cohen AE, Deisseroth K. All-optical physiol-ogy resolves a synaptic basis for behavioral timescale plasticity. Cell 2023; 186: 543-559.e19.
13. Fedele E. Anti-amyloid therapies for Alzheimer’s disease and the amyloid cascade hypothesis. Int J Mol Sci 2023; 24: 14499.
14. Fernandez de Sevilla D, Nunez A, Araque A, Buño W. Metabotropic regulation of synaptic plasticity. Neuroscience 2021; 456: 1-3.
15. Foley K, McKee C, Nairn AC, Xia H. Regulation of synaptic transmission and plasticity by protein phosphatase 1. J Neurosci 2021; 41: 3040-3050.
16. Giuffrida ML. Amyloid beta and Alzheimer’s disease: Molecular updates from physiology to pathology. Int J Mol Sci 2023; 24: 7913.
17. Goto A. Synaptic plasticity during systems memory consolidation. Neurosci Res 2022; 183: 1-6.
18. Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rab-inovici GD, Schott JM, Jones DT, Murray ME. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol 2021; 20: 222-234.
19. Guo L, Tian J, Du H. Mitochondrial dysfunction and synaptic transmission failure in Alz-heimer’s disease. J Alzheimers Dis 2017; 57: 1071-1086.
20. Gupta KK, Singh SK. Cdk5: A main culprit in neurodegeneration. Int J Neurosci 2019; 129: 1192-1197.
21. Hamano T, Enomoto S, Shirafuji N, Ikawa M, Yamamura O, Yen SH, Nakamoto Y. Autophagy and tau protein. Int J Mol Sci 2021; 22: 7475.
22. He X, Li J, Zhou G, Yang J, McKenzie S, Li Y, Li W, Yu J, Wang Y, Qu J, Wu Z, Hu H, Duan S, Ma H. Gating of hippocampal rhythms and memory by synaptic plasticity in inhibitory inter-neurons. Neuron 2021; 109: 1013-1028.e9.
23. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.
24. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14: 388-405.
25. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol 2015; 16: 229-236.
26. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015; 16: 358-372.
27. Hikosaka K, Yaku K, Okabe K, Nakagawa T. Implications of NAD metabolism in pathophysi-ology and therapeutics for neurodegenerative diseases. Nutr Neurosci 2021; 24: 371-383.
28. Horrigan J, Gomes TB, Snape M, Nikolenko N, McMorn A, Evans S, Yaroshinsky A, Della Pasqua O, Oosterholt S, Lochmüller H. A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1). Pediatr Neurol 2020; 112: 84-93.
29. Huang YK, Liu CC, Wang S, Cheng HC, Meadows C, Chang KC. The role of aldose reduc-tase in beta-amyloid-induced micro-glia activation. Int J Mol Sci 2022; 23: 15088.
30. Hur JY. Gamma-secretase in Alzheimer’s disease. Exp Mol Med 2022; 54: 433-446.
31. Imbimbo BP, Ippati S, Watling M, Imbimbo C. Role of monomeric amyloid-beta in cognitive performance in Alzheimer’s disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacol Res 2023; 187: 106631.
32. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, VieiraSaecker A, Schwartz S, Albas-set S, McManus RM, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock DT, Blum D, Latz E, Buée L, Heneka MT. NLRP3 inflammasome activation drives tau pathology. Nature 2019; 575: 669-673.
33. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E,
34. Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535-562.
35. Jung CK, Keppler K, Steinbach S, Blazquez-Llorca L, Herms J. Fibrillar amyloid plaque for-mation precedes microglial activation. PLoS One 2015; 10: e0119768.
36. Keifer J. Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease. J Neurosci Res 2022; 100: 979-991.
37. Kim DW, Tu KJ, Wei A, Lau AJ, Gonzalez-Gil A, Cao T, Braunstein K, Ling JP, Troncoso JC, Wong PC, Blackshaw S, Schnaar RL, Li T. Amyloid-beta and tau pathologies act synergistical-ly to induce novel disease stage-specific microglia subtypes. Mol Neurodegener 2022; 17: 83.
38. Koch G, Spampinato D. Alzheimer disease and neuroplasticity. Handb Clin Neurol 2022; 184: 473-479.
39. Kumari S, Dhapola R, Reddy DH. Apoptosis in Alzheimer’s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis 2023; 28: 943-957.
40. Lamontagne-Kam D, Ulfat AK, Hervé V, Vu TM, Brouillette J. Implication of tau propagation on neurodegeneration in Alzheimer’s disease. Front Neurosci 2023; 17: 1219299.
41. Lee TH, Fukui T, Weinstein MC, Tosteson AN, Goldman L. Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina. Med Decis Mak-ing 1988; 8: 268-278.
42. Lei L, Feng J, Wu G, Wei Z, Wang JZ, Zhang B, Liu R, Liu F, Wang X, Li HL. HIF-1alpha causes LCMT1/PP2A deficiency and mediates tau hyperphosphorylation and cognitive dys-function during chronic hypoxia. Int J Mol Sci 2022; 23: 16140.
43. Lei P, Ayton S, Bush AI. The essential elements of Alzheimer’s disease. J Biol Chem 2021; 296: 100105.
44. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 2021; 17: 157-172.
45. Li L, Ru Q, Lu Y, Fang X, Chen G, Saifullah AB, Yao C, Tolias KF. Tiam1 coordinates synap-tic structural and functional plasticity underpinning the pathophysiology of neuropathic pain. Neuron 2023; 111: 2038-2050.e6.
46. Li S, Olde Heuvel F, Rehman R, Aousji O, Froehlich A, Li Z, Jark R, Zhang W, Conquest A, Woelfle S, Schoen M, Meara CCO, Reinhardt RL, Voehringer D, Kassubek J, Ludolph A, Hu-ber-Lang M, Knöll B, Morganti-Kossmann MC, Brockmann MM, Boeckers T, Roselli F. Inter-leukin-13 and its receptor are synaptic proteins involved in plasticity and neuroprotection. Nat Commun 2023; 14: 200.
47. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Abeta oligo-mers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31: 6627-6638.
48. Liu X, Che R, Liang W, Zhang Y, Wu L, Han C, Lu H, Song W, Wu Y, Wang Z. Clusterin transduces Alzheimer-risk signals to amyloidogenesis. Signal Transduct Target Ther 2022; 7: 325.
49. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev 2017; 2017: 2525967.
50. Lopes DM, Wells JA, Ma D, Wallis L, Park D, Llewellyn SK, Ahmed Z, Lythgoe MF, Harri-son IF. Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model. Alzheimers Res Ther 2024; 16: 71.
51. Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. A phase II trial of tideglusib in Alz-heimer’s disease. J Alzheimers Dis 2015; 45: 75-88.
52. Luca M, Di Mauro M, Di Mauro M, Luca A. Gut microbiota in Alzheimer’s disease, depres-sion, and type 2 diabetes mellitus: the role of oxidative stress. Oxid Med Cell Longev 2019; 2019: 4730539.
53. Maitra S, Vincent B. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alz-heimer’s disease: Mechanisms and possible therapeutic interventions. Life Sci 2022; 308: 120986.
54. Mohamed Asik R, Suganthy N, Aarifa MA, Kumar A, Szigeti K, Mathe D, Gulyás B, Ar-chunan G, Padmanabhan P. Alzheimer’s disease: A molecular view of b-amyloid induced mor-bific events. Biomedicines 2021; 9: 1126.
55. Monteiro AR, Barbosa DJ, Remiao F, Silva R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol 2023; 211: 115522.
56. Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, Torsetnes SB, Grøntvedt GR, Waterloo KK, Aarsland D, Nilsson LNG, Fladby T. Glial activation and in-flammation along the Alzheimer’s disease continuum. J Neuroinflammation 2019; 16: 46.
57. Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol 2022; 21: 726-734.
58. Pahlavani HA. Exercise therapy to prevent and treat Alzheimer’s disease. Front Aging Neurosci 2023; 15: 1243869.
59. Pomeshchik Y, Velasquez E, Gil J, Klementieva O, Gidlöf R, Sydoff M, Bagnoli S, Nacmias B, Sorbi S, Westergren-Thorsson G, Gouras GK, Rezeli M, Roybon L. Proteomic analysis across patient iPSC-based models and human post-mortem hippocampal tissue reveals early cellular dysfunction and progression of Alzheimer’s disease pathogenesis. Acta Neuropathol Commun 2023; 11: 150.
60. Rezai AR, D’Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K, Mehta RI, Wang P, Najib U, Teixeira CVL, Arsiwala T, Tarabishy A, Tirumalai P, Claassen DO, Hodder S, Haut MW. Ultrasound blood-brain barrier opening and aducanumab in Alzheimer’s disease. N Engl J Med 2024; 390: 55-62.
61. Roesler R, Parent MB, LaLumiere RT, McIntyre CK. Amygdalahippocampal interactions in synaptic plasticity and memory formation. Neurobiol Learn Mem 2021; 184: 107490.
62. Sedzikowska A, Szablewski L. Insulin and insulin resistance
63. in Alzheimer’s disease. Int J Mol Sci 2021; 22: 9987.
64. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
65. Shinohara M, Tachibana M, Kanekiyo T, Bu G. Role of LRP1 in the pathogenesis of Alz-heimer’s disease: evidence from clinical and preclinical studies. J Lipid Res 2017; 58: 1267-1281.
66. Singh N, Nandy SK, Jyoti A, Saxena J, Sharma A, Siddiqui AJ, Sharma L. Protein kinase C (PKC) in neurological health: implications for Alzheimer’s disease and chronic alcohol con-sumption. Brain Sci 2024; 14: 554.
67. Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: Friend or foe? Mol Neu-robiol 2017; 54: 8071-8089.
68. Soderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, Möller C, Lannfelt L. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics 2023; 20: 195-206.
69. Sun BL, Chen Y, Fan DY, Zhu C, Zeng F, Wang YJ. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. Sci China Life Sci 2021; 64: 926-937.
70. Tanaka T, Ohashi S, Takashima A, Kobayashi S. Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hy-perphosphorylation. Biochim Biophys Acta Gen Subj 2022; 1866: 130135.
71. Temviriyanukul P, Chansawhang A, Karinchai J, Phochantachinda S, Buranasinsup S, Intha-chat W, Pitchakarn P, Chantong B. Kaempferia parviflora extracts protect neural stem cells from amyloid peptide-mediated inflammation in co-culture model with microglia. Nutrients 2023; 15: 1098.
72. Teng E, Manser PT, Pickthorn K, et al., Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol, 2022. 79(8): p. 758-767.
73. Tian, Y., G. Jing, and M. Zhang, Insulin-degrading enzyme: Roles and pathways in ameliorat-ing cognitive impairment associated with Alzheimer’s disease and diabetes. Ageing Res Rev, 2023. 90: p. 101999.
74. Van Acker, Z.P., A. Perdok, M. Bretou, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators., The microglial lysosomal system in Alzheimer’s dis-ease: Guardian against proteinopathy. Ageing Res Rev 2021; 71: 101444.
75. van Oostveen WM, de Lange ECM. Imaging techniques in Alzheimer’s disease: A review of applications in early diagnosis and longitudinal monitoring. Int J Mol Sci 2021; 22: 2110.
76. Vints WAJ, Levin O, Fujiyama H, Verbunt J, Masiulis N. Exerkines and long-term synaptic po-tentiation: Mechanisms of exercise-induced neuroplasticity. Front Neuroendocrinol 2022; 66: 100993.
77. Wang CS, Kavalali ET, Monteggia LM. BDNF signaling in context: From synaptic regulation to psychiatric disorders. Cell 2022; 185: 62-76.
78. Wang F, Chen D, Wu P, et al. Formaldehyde, epigenetics, and Alzheimer’s disease. Chem Res Toxicol 2019; 32: 820-830.
79. Wang H, Huang S, Yan K, Fang X, Abussaud A, Martinez A, Sun HS, Feng ZP. Tideglusib, a chemical inhibitor of GSK3-beta, attenuates hypoxic-ischemic brain injury in neonatal mice. Bi-ochim Biophys Acta 2016; 1860: 2076-2085.
80. Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, Lei T, Hou J, Cai Z, Cella M, Nguyen K, Poliani PL, Beatty WL, Chen Y, Cao S, Lin K, Rodrigues C, Ellebedy AH, Gilfillan S, Brown GD, Holtz-
81. man DM, Brioschi S, Colonna M. TREM2 drives microglia response to amy-loid-beta via SYK-dependent and -independent pathways. Cell 2022; 185: 4153-4169.e19.
82. Wang W, Zhou Q, Jiang T, Li S, Ye J, Zheng J, Wang X, Liu Y, Deng M, Ke D, Wang Q, Wang Y, Wang JZ. A novel small-molecule PROTAC selectively promotes tau clearance to im-prove cognitive functions in Alzheimer-like models. Theranostics 2021; 11: 5279-5295.
83. Wang W, Li Y, Ma F, Sheng X, Chen K, Zhuo R, Wang C, Zheng H, Zhang YW, Bu G, Chen XF, Zhong L. Microglial repopulation reverses cognitive and synaptic deficits in an Alz-heimer’s disease model by restoring BDNF signaling. Brain Behav Immun 2023; 113: 275-288.
84. Wegmann S, Biernat J, Mandelkow E. A current view on Tau protein phosphorylation in Alz-heimer’s disease. Curr Opin Neurobiol 2021; 69: 131-138.
85. Williams JB, Cao Q, Wang W, Lee YH, Qin L, Zhong P, Ren Y, Ma K, Yan Z. Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model. Nat Commun 2023; 14: 91.
86. Wu JJ, Yang Y, Wan Y, Xia J, Xu JF, Zhang L, Liu D, Chen L, Tang F, Ao H, Peng C. New in-sights into the role and mechanisms of ginsenoside Rg1 in the management of Alzheimer’s dis-ease. Biomed Pharmacother 2022; 152: 113207.
87. Yang X, Yang W, Xia X, Lei T, Yang Z, Jia W, Zhou Y, Cheng G, Gao H. Intranasal Delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for Alzheimer’s dis-ease therapy. Small 2022; 18: e2203182.
88. Yang Y, Mohammed FS, Zhang N, Sauve AA. Dihydronicotinamide riboside is a potent NAD(+) concentration enhancer in vitro and in vivo. J Biol Chem 2019; 294: 9295-9307.
89. Yasuda R, Hayashi Y, Hell JW. CaMKII: a central molecular organizer of synaptic plasticity, learning and memory. Nat Rev Neurosci 2022; 23: 666-682.
90. Yu CJ, Wang M, Li RY, Wei T, Yang HC, Yin YS, Mi YX, Qin Q, Tang Y. TREM2 and micro-glia contribute to the synaptic plasticity: from physiology to pathology. Mol Neurobiol 2023; 60: 512-523.
91. Zhang H, Wei W, Zhao M, Ma L, Jiang X, Pei H, Cao Y, Li H. Interaction between Abeta and Tau in the pathogenesis of Alzheimer’s disease. Int J Biol Sci 2021; 17: 2181-2192.
92. Zhang H, Wang X, Xu P, Ji X, Chi T, Liu P, Zou L. Tolfenamic acid inhibits GSK-3beta and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models. J Physiol Sci 2020; 70: 29.
93. Zhang H, Bramham CR. Arc/Arg3.1 function in long-term synaptic plasticity: Emerging mech-anisms and unresolved issues. Eur J Neurosci 2021; 54: 6696-6712.
94. Zhang P, Kishimoto Y, Grammatikakis I, Gottimukkala K, Cut-ler RG, Zhang S, Abdelmohsen K, Bohr VA, Sen JM, Gorospe M, Mattson MP. Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat Neurosci 2019; 22: 719-728.
95. Zhang Q, Xia Y, Wang Y, Shentu Y, Zeng K, Mahaman YAR, Huang F, Wu M, Ke D, Wang Q, Zhang B, Liu R, Wang JZ, Ye K, Wang X. CK2 phosphorylating I(2)(PP2A)/SET mediates tau pathology and cognitive impairment. Front Mol Neurosci 2018; 11: 146.
96. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 2021; 8: 313-321.
97. Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid beta-based therapy for Alzheimer’s dis-ease: challenges, successes and future. Signal Transduct Target Ther 2023; 8: 248.
98. Zhu B, Liu Y, Hwang S, Archuleta K, Huang H, Campos A, Murad R, Piña-Crespo J, Xu H, Huang TY. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol Neurodegener 2022; 17: 58.
Copyright: © 2025 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.